O'Shaughnessy Ventures Bets $100K on AI-Driven Cell Regeneration Research — O'Shaughnessy Ventures LLC

Event summary

O'Shaughnessy Ventures awarded a $100,000 fellowship to Wiktoria Pawlak to develop an AI model decoding cellular electrical signals for regenerative therapies.
Pawlak's research focuses on identifying electrical patterns in cells to predict tissue health and disease progression, starting with cancer.
The 12-month project aims to validate a proof-of-concept model for electroceutical therapies that use electrical signals instead of drugs.
Pawlak, a bioengineer and AI researcher based in Poland, has a background in cardiac-cell microscopy and glial cell signal modeling.
O'Shaughnessy Ventures has awarded 20 fellowships in 2026, with applications for the next round opening January 1, 2027.

The big picture

O'Shaughnessy Ventures' investment in Pawlak's research aligns with the growing trend of using AI to decode biological signals for therapeutic purposes. This approach could disrupt traditional drug development by offering non-pharmacological treatments, potentially reducing side effects and improving patient outcomes. The fellowship program reflects a broader strategy of backing high-potential, interdisciplinary research that combines bioengineering and artificial intelligence.

What we're watching

Proof of Concept: Whether Pawlak's AI model can successfully identify and validate key electrical patterns in cellular regeneration within the 12-month timeline.
Therapeutic Applications: How quickly the research can transition from cancer models to other disease areas, expanding the potential market for electroceutical therapies.
Industry Adoption: The pace at which biotech and pharmaceutical companies integrate AI-driven electroceutical approaches into their pipelines, given the shift away from traditional drug-based treatments.